Experts in the field of Oncology attended and provided insightful new information on the latest innovations and developments in Oncology, the study and treatment of cancer.
More than 400 leading doctors from around 21 countries attended the conference from the Middle East, North Africa, South East Asia and South Africa. The main focus of the meeting was on the development and research of drugs affecting cancer.
"Breast cancer strikes more women than any other type of cancer. Approximately 1.2 million women worldwide were diagnosed with breast cancer in 2000. We at Roche are committed to cancer patients and to the professionals who treat them." said Ekkehard Betsch, General Manager Middle East, Hoffmann-La Roche Ltd. "We realise the importance of continuing to invest in new ways to treat people with this disease and are devoted to ensuring that we inform doctors in the region of the latest developments and treatments in breast cancer."
Within the last five years Roche has become the world's leading provider of anti-cancer treatments. Roche's Oncology portfolio includes a combination of proven products and new innovative ones. The portfolio includes three breakthrough products: Herceptin®, MabThera® and Xeloda®, which all treat a range of malignancies including breast cancer, non-Hodgkin's lymphoma and colorectal cancer. All three products are revolutionary and offer increased survival benefit.
As a world leader in oncology, Roche continues to test and research new products such as Avastin®, a protein that is believed to play an important role in tumor angiogenesis. Avastin interferes with the blood supply to tumors, thereby inhibiting tumor growth and potentially leading to tumor regression. Bondronat®, significantly reduces the incidence of cancer related bone complications and reduces bone pain in patients with breast cancer, is another example of Roche's continual innovation.
Browse
related articles
Second Middle East Oncology Meeting hosted in Dubai
- United Arab Emirates: Thursday, January 15 - 2004 at 13:09
- PRESS RELEASE
Related content
Hoffmann-La Roche Ltd., one of the world's leading healthcare companies, hosted its Second Middle East Oncology Meeting in Dubai, UAE on January 14th and 15th.
Dr. Hamdy Abdel Azim, Professor of Clinical Oncology at Cairo University, presents at the 2nd Roche Middle East Oncology Conference held in Dubai from 14-15 January. Hoffmann-La Roche Ltd., one of the world's leading healthcare companies, hosted the conference, bringing doctor's from around the region to share their expertise in Oncology. Dr. Abdel Azim enlightned attendees with his research and knowledge of Herceptin, a targeted treatment for metastatic breast cancer.
Article Options
Log in to request more information from Hoffmann La-Roche
Posted by Anne-Birte Stensgaard, Senior News EditorThursday, January 15 - 2004 at 13:09 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Notes and Media Contacts »
About Roche
Roche is a leading healthcare company based in Switzerland with a history of more than 100 years in the discovery, development, production and marketing of cost-effective prescription drugs of high quality. Many of them represent true breakthroughs in combating human diseases. Innovative medicines have always been the base for best possible therapy.
The Roche Oncology mission is to provide healthcare professionals who treat patients suffering from cancer with unique targeted healthcare solutions. This is driven by an integrated approach which combines the skills of a world-leading Diagnostics Division with a Pharmaceuticals Division whose commitment is to the research, development and marketing of novel anticancer agents. The Roche commitment is highlighted by a highly innovative portfolio of currently marketed oncology products and new ones under research.
Product Background
Xeloda ® (capecitabine)
Xeloda is an effective new oral chemotherapy that was introduced as a way to target the cancer-killing agent straight into the cancer. It targets where needed and has less effect on healthy cells in the body for example: cells responsible for hair growth. Xeloda tablets improve the daily lives of women with breast cancer by giving them the freedom to live their lives, avoid problems with i.v. lines and take their treatment at home. In addition., Xeloda is among the very few agents that has demonstrated a survival benefit, and extraordinary tumour control rates, in women with breast cancer that has spread. Xeloda is prescribed for treatment of colon, rectal or breast cancer.
Herceptin® (trastuzumab)
Herceptin is the first monoclonal antibody (MAb) designed to target and block the function of HER2, a protein found in excessive amounts on the surface of some breast cancer cells. It is the first therapy to target a gene that plays a role in the actual development of the cancer and most importantly, recent findings suggest that it results in significant benefits when compared to standard treatment.
MabThera® (rituximab)
MabThera is the world's first licensed monoclonal antibody therapy for the targeted treatment of non-Hodgkin's lymphoma (NHL). More than 85% of all NHLs are derived from B-cells. Unlike many traditional forms of treatment, MabThera specifically targets B-cells. Patients treated with MabThera are disease free for longer as opposed to chemotherapy where patients relapse eventually
Recormon® (epoetin beta)
Recormon is used to treat anaemia in cancer patients. Anaemia, an abnormal low red blood cell count is a frequent complication in patients with cancer. In fact, 30-40% of patients with non-Hodgkin's lymphoma are anaemic at diagnosis and 70% are anaemic during chemotherapy. Recormon has significantly improved the outlook for people with cancer-related anaemia by rapidly increasing red blood cell production within just a few days of treatment.
Issued on behalf of Hoffmann- La Roche by Promoseven Weber Shandwick, Dubai.
For more information, please contact:
Joanne Kubba
Tel: 04 321 0077
Fax: 04 321 1711
Roche is a leading healthcare company based in Switzerland with a history of more than 100 years in the discovery, development, production and marketing of cost-effective prescription drugs of high quality. Many of them represent true breakthroughs in combating human diseases. Innovative medicines have always been the base for best possible therapy.
The Roche Oncology mission is to provide healthcare professionals who treat patients suffering from cancer with unique targeted healthcare solutions. This is driven by an integrated approach which combines the skills of a world-leading Diagnostics Division with a Pharmaceuticals Division whose commitment is to the research, development and marketing of novel anticancer agents. The Roche commitment is highlighted by a highly innovative portfolio of currently marketed oncology products and new ones under research.
Product Background
Xeloda ® (capecitabine)
Xeloda is an effective new oral chemotherapy that was introduced as a way to target the cancer-killing agent straight into the cancer. It targets where needed and has less effect on healthy cells in the body for example: cells responsible for hair growth. Xeloda tablets improve the daily lives of women with breast cancer by giving them the freedom to live their lives, avoid problems with i.v. lines and take their treatment at home. In addition., Xeloda is among the very few agents that has demonstrated a survival benefit, and extraordinary tumour control rates, in women with breast cancer that has spread. Xeloda is prescribed for treatment of colon, rectal or breast cancer.
Herceptin® (trastuzumab)
Herceptin is the first monoclonal antibody (MAb) designed to target and block the function of HER2, a protein found in excessive amounts on the surface of some breast cancer cells. It is the first therapy to target a gene that plays a role in the actual development of the cancer and most importantly, recent findings suggest that it results in significant benefits when compared to standard treatment.
MabThera® (rituximab)
MabThera is the world's first licensed monoclonal antibody therapy for the targeted treatment of non-Hodgkin's lymphoma (NHL). More than 85% of all NHLs are derived from B-cells. Unlike many traditional forms of treatment, MabThera specifically targets B-cells. Patients treated with MabThera are disease free for longer as opposed to chemotherapy where patients relapse eventually
Recormon® (epoetin beta)
Recormon is used to treat anaemia in cancer patients. Anaemia, an abnormal low red blood cell count is a frequent complication in patients with cancer. In fact, 30-40% of patients with non-Hodgkin's lymphoma are anaemic at diagnosis and 70% are anaemic during chemotherapy. Recormon has significantly improved the outlook for people with cancer-related anaemia by rapidly increasing red blood cell production within just a few days of treatment.
Issued on behalf of Hoffmann- La Roche by Promoseven Weber Shandwick, Dubai.
For more information, please contact:
Joanne Kubba
Tel: 04 321 0077
Fax: 04 321 1711
Disclaimer »
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
